Ocular Surface Disease in Glaucoma Patients

References

• Nijm LM, De Benito-Llopis L, Rossi GC, Vajaranant TS, Coroneo MT. Understanding the dual dilemma of dry eye and glaucoma: an international review. Asia Pac J Ophthalmol. 2020;9(6):481–490. doi:10.1097/APO.0000000000000327.
   PubMed Web of Science ®Google Scholar
• Asiedu K, Abu SL. The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: a review. J Curr Ophthalmol. 2019;31(1):8–15. doi:10.1016/j.joco.2018.07.003.
   PubMed Web of Science ®Google Scholar
• Ferreras A, Figus M, Fogagnolo P, Iester M, Frezzotti P. Managing side effects on ocular surface caused by glaucoma eye drops. Curr Med Chem. 2019;26(22):4223–4224. doi:10.2174/092986732622190920092210.
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye. 2022;36(2):361–368. doi:10.1038/s41433-021-01668-x.
   PubMed Web of Science ®Google Scholar
• Kaštelan S, Tomić M, Metež Soldo K, Salopek-Rabatić J. How ocular surface disease impacts the glaucoma treatment outcome. Biomed Res Int. 2013;2013:696328–696327. 2013: doi:10.1155/2013/696328.
   PubMed Web of Science ®Google Scholar
• Mylla Boso AL, Gasperi E, Fernandes L, Costa VP, Alves M. Impact of ocular surface disease treatment in patients with glaucoma. Clin Ophthalmol. 2020;14:103–111. doi:10.2147/OPTH.S229815.
   PubMed Web of Science ®Google Scholar
• Voicu L, Salim S. New strategies for the management of ocular surface disease in glaucoma patients. Curr Opin Ophthalmol. 2021;32(2):134–140. doi:10.1097/ICU.0000000000000739.
   PubMed Web of Science ®Google Scholar
• Rossi GCM, Pasinetti GM, Scudeller L, Bianchi PE. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther. 2013;29(4):390–394. doi:10.1089/jop.2011.0159.
   PubMed Web of Science ®Google Scholar
• Guarnieri A, Carnero E, Bleau AM, Alfonso-Bartolozzi B, Moreno-Montañés J. Relationship between OSDI questionnaire and ocular surface changes in glaucomatous patients. Int Ophthalmol. 2020;40(3):741–751. doi:10.1007/s10792-019-01236-z.
   PubMed Web of Science ®Google Scholar
• Stalmans I, Lemij H, Clarke J, Baudouin C. Signs and symptoms of ocular surface disease: the reasons for patient dissatisfaction with glaucoma treatments. Clin Ophthalmol. 2020;14:3675–3680. doi:10.2147/OPTH.S269586.
   PubMed Web of Science ®Google Scholar
• Lajmi H, Chelly Z, Choura R, Mansour KB, Hmaied W. Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops. J Fr Ophtalmol. 2021;44(9):1326–1331. doi:10.1016/j.jfo.2021.03.008.
   PubMedGoogle Scholar
• Carnevale C, Riva I, Roberti G, Michelessi M, Tanga L, Verticchio Vercellin AC, Agnifili L, Manni G, Harris A, Quaranta L, et al. Confocal microscopy and anterior segment optical coherence tomography imaging of the ocular surface and bleb morphology in medically and surgically treated glaucoma patients: a review. Pharmaceuticals. 2021;14(6):581. doi:10.3390/ph14060581.
   Web of Science ®Google Scholar
• Mastropasqua L, Agnifili L, Mastropasqua R, Fasanella V. Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma. Curr Opin Pharmacol. 2013;13(1):56–64. doi:10.1016/j.coph.2012.10.002.
   PubMed Web of Science ®Google Scholar
• Zaleska-Żmijewska A, Strzemecka E, Wawrzyniak ZM, Szaflik JP. Extracellular MMP-9-based assessment of ocular surface inflammation in patients with primary open-angle glaucoma. J Ophthalmol. 2019;2019:1–7. 2019: doi:10.1155/2019/1240537.
   Web of Science ®Google Scholar
• Dubrulle P, Labbé A, Brasnu E, Liang H, Hamard P, Meziani L, Baudouin C. Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases. J Glaucoma. 2018;27(12):1105–1111. doi:10.1097/IJG.0000000000001041.
   PubMed Web of Science ®Google Scholar
• El Ameen A, Vandermeer G, Khanna RK, Pisella PJ. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. Eur J Ophthalmol. 2019;29(6):645–653. doi:10.1177/1120672118805877.
   PubMed Web of Science ®Google Scholar
• Economou MA, Laukeland H, Grabska-Liberek I, Rouland JF. Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. Clin Ophthalmol. 2018;12:2399–2407. doi:10.2147/OPTH.S176605.
   PubMed Web of Science ®Google Scholar
• Ahmed IK, Baudouin C, Gupta PK, Radcliffe NM. Ocular surface disease: an unexpected driver of adverse outcomes in glaucoma. EyeNet. 2021;2021:1–11.
   Google Scholar
• Lajmi H, Hmaied W, Achour B, Zahaf A. Risk factors for ocular surface disease in Tunisian users of preserved antiglaucomatous eye drops. J Curr Ophthalmol. 2021;33(2):128–135. doi:10.4103/JOCO.JOCO_226_20.
   PubMed Web of Science ®Google Scholar
• Sahlu M, Giorgis AT. Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia. BMC Ophthalmol. 2021;21(1):155. doi:10.1186/s12886-021-01917-3.
   PubMed Web of Science ®Google Scholar
• Elhusseiny AM, Khalil AA, El Sheikh RH, Bakr MA, Eissa MG, El Sayed YM. New approaches for diagnosis of dry eye disease. Int J Ophthalmol. 2019;12(10):1618–1628. doi:10.18240/ijo.2019.10.15.
   PubMed Web of Science ®Google Scholar
• Elhusseiny AM, Eleiwa TK, Yacoub MS, George J, ElSheikh RH, Haseeb A, Kwan J, Elsaadani IA, Abo Shanab SM, Solyman O, et al. Relationship between screen time and dry eye symptoms in pediatric population during the COVID-19 pandemic. Ocul Surf. 2021;22:117–119. doi:10.1016/j.jtos.2021.08.002.
   PubMed Web of Science ®Google Scholar
• Vasile P. Ocular surface – a complex and vulnerable adoptive environment for topical glaucoma treatment. Rom J Ophthalmol. 2016;60(3):153–157.
   PubMedGoogle Scholar
• Güçlü H, Çınar AK, Çınar AC, Akaray İ, Şambel Aykutlu M, Sakallıoğlu AK, Gürlü V. Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study. Cutan Ocul Toxicol. 2021;40(2):85–94. doi:10.1080/15569527.2021.1902341.
   PubMed Web of Science ®Google Scholar
• Muthusamy K, Tuft SJ. Iatrogenic limbal stem cell deficiency following drainage surgery for glaucoma. Can J Ophthalmol. 2018;53(6):574–579. doi:10.1016/j.jcjo.2018.01.037.
   PubMed Web of Science ®Google Scholar
• Figus M, Agnifili L, Lanzini M, Brescia L, Sartini F, Mastropasqua L, Posarelli C. Topical preservative-free ophthalmic treatments: an unmet clinical need. Expert Opin Drug Deliv. 2021;18(6):655–672. doi:10.1080/17425247.2021.1860014.
   PubMed Web of Science ®Google Scholar
• Shen W, Huang B, Yang J. Ocular surface changes in prostaglandin analogue-treated patients. J Ophthalmol. 2019;2019:9798272–9798277. 2019: doi:10.1155/2019/9798272.
   PubMed Web of Science ®Google Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22(9):730–735. doi:10.1097/IJG.0b013e31825af67d.
   PubMed Web of Science ®Google Scholar
• Herman DC, Gordon MO, Beiser JA, Chylack LT, Lamping KA, Schein OD, Soltau JB, Kass MA. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am J Ophthalmol. 2006;142(5):800–810.e1. doi:10.1016/j.ajo.2006.06.052.
   PubMed Web of Science ®Google Scholar
• Muzychuk A, Racine L, Robert MC, Birt C, Penner V, Harasymowycz P, Crichton A, Ford B, Gooi P, Harissi-Dagher M. Management of ocular surface disease in glaucoma: a survey of canadian glaucoma specialists. J Glaucoma. 2020;29(12):1162–1172. doi:10.1097/IJG.0000000000001659.
   PubMed Web of Science ®Google Scholar
• Sencanic I, Gazibara T, Dotlic J, Stamenkovic M, Jaksic V, Bozic M, Grgurevic A. Validation of the glaucoma quality of life-15 questionnaire in Serbian language. Int J Ophthalmol. 2018;11(10):1674–1684. doi:10.18240/ijo.2018.10.16.
   PubMed Web of Science ®Google Scholar
• Jamerson EC, Elhusseiny AM, ElSheikh RH, Eleiwa TK, El Sayed YM. Role of matrix metalloproteinase 9 in ocular surface disorders. Eye Contact Lens. 2020;46(Suppl 2):S57–S63. doi:10.1097/ICL.0000000000000668.
   PubMed Web of Science ®Google Scholar
• Katsanos A, Riva I, Bozkurt B, Holló G, Quaranta L, Oddone F, Irkec M, Dutton GN, Konstas AG. A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. Expert Opin Drug Saf. 2021;2021:1–15. doi:10.1080/14740338.2022.1996560.
   Web of Science ®Google Scholar
• Tang W, Zhang F, Liu K, Duan X. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta-analysis. Medicine. 2019;98(30):e16597. doi:10.1097/MD.0000000000016597.
   PubMed Web of Science ®Google Scholar
• Su C-C, Lee Y-C, Lee PRC. Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study. Graefes Arch Clin Exp Ophthalmol. 2021;259(5):1243–1251. doi:10.1007/s00417-020-05067-y.
   PubMed Web of Science ®Google Scholar
• Seong HJ, Lee K, Lee SJ, Kim S, Park JW. Efficacy and safety of preservative-free latanoprost eyedrops compared with preserved prostaglandin analogues in patients with open-angle glaucoma. Korean J Ophthalmol. 2021;35(3):235–241. doi:10.3341/kjo.2021.0010.
   PubMedGoogle Scholar
• Lee SM, Jin SW. Efficacy of preservative-free latanoprost in normal-tension glaucoma with mild to moderate dry eye. J Korean Ophthalmol Soc. 2020;61(6):639–644. doi:10.3341/jkos.2020.61.6.639.
   Web of Science ®Google Scholar
• Kim DW, Shin J, Lee CK, Kim M, Lee S, Rho S. Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial. Sci Rep. 2021;11(1):14971. doi:10.1038/s41598-021-94574-x.
   PubMed Web of Science ®Google Scholar
• Harasymowycz P, Hutnik C, Rouland JF, Negrete FJM, Economou MA, Denis P, Baudouin C. Preserved versus preservative-free latanoprost for the treatment of glaucoma and ocular hypertension: a post hoc pooled analysis. Adv Ther. 2021;38(6):3019–3031. doi:10.1007/s12325-021-01731-9.
   PubMed Web of Science ®Google Scholar
• Muz OE, Dagdelen K, Pirdal T, Guler M. Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension. Int Ophthalmol. 2021;41(11):3825–3835. doi:10.1007/s10792-021-01947-2.
   PubMed Web of Science ®Google Scholar
• Kumar S, Singh T, Ichhpujani P, Vohra S, Thakur S. Correlation of ocular surface disease and quality of life in Indian Glaucoma Patients: BAC-preserved versus BAC-free Travoprost. Turk J Ophthalmol. 2020;50(2):75–81. doi:10.4274/tjo.galenos.2019.29000.
   PubMedGoogle Scholar
• Lopes NLV, Gracitelli CPB, Chalita MR. Ocular surface evaluation after the substitution of benzalkonium chloride preserved prostaglandin eye drops by a preservative-free prostaglandin analogue. Med Hypothesis Discov Innov Ophthalmol. 2019;8(1):52–56.
   PubMedGoogle Scholar
• Hagras S, Al-Duwailah OH, Nassief M, Abdelhameed A. Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma. Indian J Ophthalmol. 2021;69(9):2475. doi:10.4103/ijo.IJO_165_21.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Bányai L, Blask K-D, Väth J, Kozobolis VP, Trüb PR, Tsironi S, Maloutas S, Teus MA, Stewart WC. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. J Ocul Pharmacol Ther. 200;20(5):375–382. doi:10.1089/jop.2004.20.375.
   PubMed Web of Science ®Google Scholar
• Ruangvaravate N, Choojun K, Srikulsasitorn B, Chokboonpiem J, Asanatong D, Trakanwitthayarak S. Ocular surface changes after switching from other prostaglandins to tafluprost and preservative-free tafluprost in glaucoma patients. Clin Ophthalmol. 2020;14:3109–3119. doi:10.2147/OPTH.S264984.
   PubMed Web of Science ®Google Scholar
• Kim JM, Park SW, Seong M, Ha SJ, Lee JW, Rho S, Lee CE, Kim KN, Kim T-W, Sung KR, et al. Comparison of the safety and efficacy between preserved and preservative-free latanoprost and preservative-free tafluprost. Pharmaceuticals. 2021;14(6):501. doi:10.3390/ph14060501.
   Web of Science ®Google Scholar
• Lee SY, Lee K, Park CK, Kim S, Bae HW, Seong GJ, Kim CY. Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative-containing or preservative-free topical prostaglandin analogues. PLoS One. 2019;14(6):e0218886. doi:10.1371/journal.pone.0218886.
   PubMed Web of Science ®Google Scholar
• Lazreg S, Merad Z, Nouri MT, Garout R, Derdour A, Ghroud N, Kherroubi R, Meziane M, Belkacem S, Ouhadj O, et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. J Fr Ophtalmol. 2018;41(10):945–954. doi:10.1016/j.jfo.2018.04.012.
   PubMed Web of Science ®Google Scholar
• Kuppens EV, de Jong CA, Stolwijk TR, de Keizer RJ, van Best JA. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol. 1995;79(4):339–342. doi:10.1136/bjo.79.4.339.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12(6):486–490. doi:10.1097/00061198-200312000-00008.
   PubMed Web of Science ®Google Scholar
• Masschelein W, Rice RG. 1979. Chlorine dioxide: chemistry and environmental impact of oxychlorine compounds [Internet]. Edt. for publication in English. Ann Arbor (MI): Ann Arbor Science, 1979; ISBN 0-250-40224-6. doi:10.1002/aheh.19830110210.
   Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11(2):119–126. doi:10.1097/00061198-200204000-00007.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Schmetterer L, Katsanos A, Hutnik CML, Holló G, Quaranta L, Teus MA, Uusitalo H, Pfeiffer N, Katz LJ. Dorzolamide/timolol fixed combination: learning from the past and looking toward the future. Adv Ther. 2021;38(1):24–51. doi:10.1007/s12325-020-01525-5.
   PubMed Web of Science ®Google Scholar
• Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130(6):832–833. doi:10.1016/S0002-9394(00)00717-0.
   PubMed Web of Science ®Google Scholar
• Bacharach J, Delgado MF, Iwach AG. Comparison of the efficacy of the fixed-combination timolol/dorzolamide versus concomitant administration of timolol and dorzolamide. J Ocul Pharmacol Ther. 2003;19(2):93–96. doi:10.1089/108076803321637618.
   PubMed Web of Science ®Google Scholar
• Hutnik C. Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010;4:581–590. doi:10.2147/OPTH.S10337.
   PubMedGoogle Scholar
• Bourne RRA, Kaarniranta K, Lorenz K, Traverso CE, Vuorinen J, Ropo A. Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study. BMJ Open. 2019;9(4):e024129. doi:10.1136/bmjopen-2018-024129.
   PubMed Web of Science ®Google Scholar
• Karlova EV, Petrov SY, Germanova VN. Preservative-free fixed combination in the treatment of open-angle glaucoma and ocular hypertension: the VISIONARY Study (EUPAS22204). Vestn Oftal’mol. 2020;136(4):76–84. doi:10.17116/oftalma202013604176.
   PubMedGoogle Scholar
• Meza-Rios A, Navarro-Partida J, Armendariz-Borunda J, Santos A. Therapies based on nanoparticles for eye drug delivery. Ophthalmol Ther. 2020;9(3):1–14. doi:10.1007/s40123-020-00257-7.
   PubMed Web of Science ®Google Scholar
• Yadav KS, Rajpurohit R, Sharma S. Glaucoma: current treatment and impact of advanced drug delivery systems. Life Sci. 2019;221:362–376. doi:10.1016/j.lfs.2019.02.029.
   PubMed Web of Science ®Google Scholar
• Gulsen D, Chauhan A. Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle. Int J Pharm. 2005;292(1–2):95–117. doi:10.1016/j.ijpharm.2004.11.033.
   PubMed Web of Science ®Google Scholar
• Aref AA. Sustained drug delivery for glaucoma: current data and future trends. Curr Opin Ophthalmol. 2017;28(2):169–174. doi:10.1097/ICU.0000000000000334.
   PubMed Web of Science ®Google Scholar
• Miller PE, Eaton JS. Medical anti-glaucoma therapy: beyond the drop. Vet Ophthalmol. 2021;24(Suppl 1):2–15. doi:10.1111/vop.12843.
   PubMed Web of Science ®Google Scholar
• Gupta S, Vyas SP. Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate. Sci Pharm. 2010;78(4):959–976. doi:10.3797/scipharm.1001-06.
   PubMedGoogle Scholar
• Pang X, Li J, Pi J, Qi D, Guo P, Li N, Wu Y, Liu Z. Increasing efficacy and reducing systemic absorption of brimonidine tartrate ophthalmic gels in rabbits. Pharm Dev Technol. 2018;23(3):231–239. doi:10.1080/10837450.2017.1328693.
   PubMed Web of Science ®Google Scholar
• Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv. 2007;14(8):507–515. doi:10.1080/10717540701606426.
   PubMed Web of Science ®Google Scholar
• Gupta H, Velpandian T, Jain S. Ion- and pH-activated novel in-situ gel system for sustained ocular drug delivery. J Drug Target. 2010;18(7):499–505. doi:10.3109/10611860903508788.
   PubMed Web of Science ®Google Scholar
• Talaei S, Mahboobian MM, Mohammadi M. Investigating the ocular toxicity potential and therapeutic efficiency of in situ gel nanoemulsion formulations of brinzolamide. Toxicol Res. 2020;9(4):578–587. doi:10.1093/toxres/tfaa066.
   PubMed Web of Science ®Google Scholar
• Hathout RM, Gad HA, Abdel-Hafez SM, Nasser N, Khalil N, Ateyya T, Amr A, Yasser N, Nasr S, Metwally AA. Gelatinized core liposomes: a new Trojan horse for the development of a novel timolol maleate glaucoma medication. Int J Pharm. 2019;556:192–199. doi:10.1016/j.ijpharm.2018.12.015.
   PubMed Web of Science ®Google Scholar
• Schnichels S, Hurst J, de Vries JW, Ullah S, Frößl K, Gruszka A, Löscher M, Bartz-Schmidt KU, Spitzer MS, Herrmann A, 2021. Improved treatment options for glaucoma with brimonidine-loaded lipid DNA nanoparticles. ACS Appl Mater Interfaces. 2019;13(8):9445–9456. doi:10.1021/acs.0c18626.
   Web of Science ®Google Scholar
• Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, Venkatraman SS. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomedicine. 2012;7:123–131. doi:10.2147/IJN.S25468.
   PubMed Web of Science ®Google Scholar
• Kouchak M, Malekahmadi M, Bavarsad N, Saki Malehi A, Andishmand L. Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients. Drug Dev Ind Pharm. 2018;44(8):1239–1242. doi:10.1080/03639045.2017.1386196.
   PubMed Web of Science ®Google Scholar
• Allam A, Elsabahy M, El Badry M, Eleraky NE. Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma. Int J Pharm. 2021;598:120380. doi:10.1016/j.ijpharm.2021.120380.
   PubMed Web of Science ®Google Scholar
• Bessone CDV, Akhlaghi SP, Tártara LI, Quinteros DA, Loh W, Allemandi DA. Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma. Eur J Pharm Sci. 2021;160:105748. doi:10.1016/j.ejps.2021.105748.
   PubMed Web of Science ®Google Scholar
• Tian C, Zeng L, Tang L, Yu J, Ren M. Sustained delivery of timolol using nanostructured lipid carriers-laden soft contact lenses. AAPS PharmSciTech. 2021;22(6):212. doi:10.1208/s12249-021-02096-6.
   PubMed Web of Science ®Google Scholar
• Ciolino JB, Ross AE, Tulsan R, Watts AC, Wang R-F, Zurakowski D, Serle JB, Kohane DS. Latanoprost-eluting contact lenses in glaucomatous monkeys. Ophthalmology. 2016;123(10):2085–2092. doi:10.1016/j.ophtha.2016.06.038.
   PubMed Web of Science ®Google Scholar
• Brandt JD, Sall K, DuBiner H, Benza R, Alster Y, Walker G, Semba CP, Budenz D, Day D, Flowers B, et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 2016;123(8):1685–1694. doi:10.1016/j.ophtha.2016.04.026.
   PubMed Web of Science ®Google Scholar
• Rubião F, Araújo ACF, Sancio JB, Nogueira BS, Franca JR, Nogueira JC, Ferreira AJ, Faraco AAG, Foureaux G, Cronemberger S. Topical bimatoprost insert for primary open-angle glaucoma and ocular hypertension treatment – a phase ii controlled study. Curr Drug Deliv. 2021;18(7):1022–1026. [accessed 2021 Nov 21]doi:10.2174/1567201818666210101112256.
   PubMed Web of Science ®Google Scholar
• Perera SA, Ting DS, Nongpiur ME, Chew PT, Aquino MCD, Sng CC, Ho S-W, Aung T. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol. 2016;10:757–764. doi:10.2147/OPTH.S102181.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Walters TR, Kolko M, Coote M, Bejanian M, Goodkin ML, Guo Q, Zhang J, Robinson MR, Weinreb RN. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–1641. doi:10.1016/j.ophtha.2020.06.018.
   PubMed Web of Science ®Google Scholar
• Craven ER, Walters T, Christie WC, Day DG, Lewis RA, Goodkin ML, Chen M, Wangsadipura V, Robinson MR, Bejanian M. 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 2020;80(2):167–179. doi:10.1007/s40265-019-01248-0.
   PubMed Web of Science ®Google Scholar
• Saini M, Dhiman R, Dada T, Tandon R, Vanathi M. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye. 2015;29(6):808–814. doi:10.1038/eye.2015.40.
   PubMed Web of Science ®Google Scholar
• Shtein RM, Shen JF, Kuo AN, Hammersmith KM, Li JY, Weikert MP. Autologous serum-based eye drops for treatment of ocular surface disease: a report by the American academy of ophthalmology. Ophthalmology. 2020;127(1):128–133. doi:10.1016/j.ophtha.2019.08.018.
   PubMed Web of Science ®Google Scholar
• Yoon CH, Lee HJ, Park HY, Kim H, Kim MK, Jeoung JW, Oh JY. Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs. Int Ophthalmol. 2020;40(3):547–552. doi:10.1007/s10792-019-01211-8.
   PubMed Web of Science ®Google Scholar
• So H-R, Park HYL, Chung S-H, Kim H-S, Byun Y-S. Effect of autologous serum eyedrops on ocular surface disease caused by preserved glaucoma eyedrops. J Clin Med. 2020;9(12):3904. doi:10.3390/jcm9123904.
   PubMed Web of Science ®Google Scholar
• Anitua E, de la Sen-Corcuera B, Orive G, Sánchez-Ávila R, Heredia P, Muruzabal F, Merayo-Lloves J. Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus. Expert Opin Biol Ther. 2021;2021:1–15. doi:10.1080/14712598.2021.1945030.
   Web of Science ®Google Scholar
• Sanchez-Avila RM, Merayo-Lloves J, Fernandez ML, Rodríguez Gutiérrez LA, Rodríguez-Calvo PP, Fernandez-Vega Cueto A, Muruzabal F, Orive G, Anitua E. Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma. Int Med Case Rep J. 2018;11:97–103. doi:10.2147/IMCRJ.S153918.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Agirretxe I, Freire V, Muruzabal F, Orive G, Anitua E, Díez-Feijóo E, Acera A. Subconjunctival PRGF fibrin membrane as an adjuvant to nonpenetrating deep sclerectomy: a 2-year pilot study. Ophthalmic Res. 2018;59(1):45–52. doi:10.1159/000481535.
   PubMed Web of Science ®Google Scholar
• Soriano D, Ferrandez B, Mateo A, Polo V, Garcia-Martin E. Meibomian gland changes in open-angle glaucoma users treated with topical medication. Optom Vis Sci. 2021;98(10):1177–1182. doi:10.1097/OPX.0000000000001782.
   PubMed Web of Science ®Google Scholar
• Uzunosmanoglu E, Mocan MC, Kocabeyoglu S, Karakaya J, Irkec M. Meibomian gland dysfunction in patients receiving long-term glaucoma medications. Cornea. 2016;35(8):1112–1116. doi:10.1097/ICO.0000000000000838.
   PubMed Web of Science ®Google Scholar
• Hu J, Zhu S, Liu X. Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2022;260(1):25–39. doi:10.1007/s00417-021-05363-1.
   PubMed Web of Science ®Google Scholar
• Kasetsuwan N, Suwajanakorn D, Tantipat C, Reinprayoon U. The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clin Ophthalmol. 2020;14:2891–2902. doi:10.2147/OPTH.S259692.
   PubMed Web of Science ®Google Scholar
• Lane SS, DuBiner HB, Epstein RJ, Ernest PH, Greiner JV, Hardten DR, Holland EJ, Lemp MA, McDonald JE, Silbert DI, et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea. 2012;31(4):396–404. doi:10.1097/ICO.0b013e318239aaea.
   PubMed Web of Science ®Google Scholar
• Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016;10:1385–1396. doi:10.2147/OPTH.S109663.
   PubMed Web of Science ®Google Scholar
• Greiner JV. Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Experiment Ophthalmol. 2013;41(6):524–530. doi:10.1111/ceo.12033.
   PubMed Web of Science ®Google Scholar
• Gazzard G, Konstantakopoulou E, Garway-Heath D, Barton K, Wormald R, Morris S, Hunter R, Rubin G, Buszewicz M, Ambler G. et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology. Br J Ophthalmol. 2018;102(5):593–598. doi:10.1136/bjophthalmol-2017-310877.
   PubMed Web of Science ®Google Scholar
• Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N. et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–1516. doi:10.1016/S0140-6736(18)32213-X.
   PubMed Web of Science ®Google Scholar
• De Keyser M, De Belder M, De Groot V. Quality of life in glaucoma patients after selective laser trabeculoplasty. Int J Ophthalmol. 2017;10(5):742–748. doi:10.18240/ijo.2017.05.14.
   PubMed Web of Science ®Google Scholar
• Ang GS, Fenwick EK, Constantinou M, Gan ATL, Man REK, Casson RJ, Finkelstein EA, Goldberg I, Healey PR, Pesudovs K, et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial. Br J Ophthalmol. 2020;104(6):813–821. doi:10.1136/bjophthalmol-2018-313396.
   PubMed Web of Science ®Google Scholar
• Patel S, Pasquale LR. Glaucoma drainage devices: a review of the past, present, and future. Semin Ophthalmol. 2010;25(5–6):265–270. doi:10.3109/08820538.2010.518840.
   PubMed Web of Science ®Google Scholar
• El Sayed YM, Elhusseiny AM, Albalkini AS, El Sheikh RH, Osman MA. C-augmented phacotrabeculectomy versus phacoemulsification in primary angle-closure glaucoma: a randomized controlled study. J Glaucoma. 2019;28(10):911–915. doi:10.1097/IJG.0000000000001345.
   PubMed Web of Science ®Google Scholar
• Agnifili L, Brescia L, Oddone F, Sacchi M, D’Ugo E, Di Marzio G, Perna F, Costagliola C, Mastropasqua R. The ocular surface after successful glaucoma filtration surgery: a clinical, in vivo confocal microscopy, and immune-cytology study. Sci Rep. 2019;9(1):11299. doi:10.1038/s41598-019-47823-z.
   PubMed Web of Science ®Google Scholar